P4787Investigating the molecular mechanisms of carfilzomib-induced cardiotoxicity and the emerging role of metformin as a prophylactic therapy

Georgios Kremastiotis; Panagiotis Efentakis; Aimilia Varela; Constantinos H. Davos; Eleni‐Dimitra Papanagnou; Ioannis P. Trougakos; Efstathios Kastritis; Zoi Kanaki; Efstathios K. Iliodromitis; Apostolos Klinakis; Meletios A Dimopoulos; Evangelos Terpos; Ioanna Andreadou

doi:10.1093/eurheartj/ehy563.p4787

Related publications

Article2018

Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin

Panagiotis Efentakis, Georgios Kremastiotis, Aimilia Varela, Panagiota Nikolaou, Eleni‐Dimitra Papanagnou, Constantinos H. Davos, Maria Tsoumani, Georgios Agrogiannis, Anastasia Konstantinidou, Efstathios Kastritis, Zoi Kanaki, Efstathios K. Iliodromitis, Apostolos Klinakis, Meletios A Dimopoulos, Ioannis P. Trougakos, Ioanna Andreadou, Evangelos Terpos

Article2021

Elucidating Carfilzomib’s Induced Cardiotoxicity in an In Vivo Model of Aging: Prophylactic Potential of Metformin

Panagiotis Efentakis, Garyfalia Psarakou, Aimilia Varela, Eleni‐Dimitra Papanagnou, Michail Chatzistefanou, Panagiota Nikolaou, Constantinos H. Davos, Maria Gavriatopoulou, Ioannis P. Trougakos, Meletios A Dimopoulos, Ioanna Andreadou, Evangelos Terpos

Article2018

The proteasome inhibitor carfilzomib (Cfz) induces cardiotoxicity in vivo: molecular mechanisms and the cardioprotective effect of metformin (Met)

Georgios Kremastiotis, Panagiotis Efentakis, Aimilia Varela, Constantinos H. Davos, Maria Tsoumani, Eleni‐Dimitra Papanagnou, Ioannis P. Trougakos, Efstathios Kastritis, Zoi Kanaki, Efstathios K. Iliodromitis, Apostolos Klinakis, Meletios A Dimopoulos, Evangelos Terpos, Ioanna Andreadou

Article2017

Comparison of Proteasome Inhibitors-Induced Cardiotoxicity (carfilzomib vs. bortezomib): Insights into the Molecular Mechanisms

Georgios Kremastiotis, Panagiotis Efentakis, Aimilia Varela, Constantinos H. Davos, Eleni‐Dimitra Papanagnou, Ioannis P. Trougakos, Eftathios Kastritis, Evangelia Chavdoula, Efstathios K. Iliodromitis, Apostolos Klinakis, Meletios A Dimopoulos, Ioanna Andreadou, Evangelos Terpos

Article2018

Metformin Restores AMPK Alpha-Mediated Autophagy and Prevents Carfilzomib-Induced Cardiotoxicity In Vivo

Georgios Kremastiotis, Panagiotis Efentakis, Aimilia Varela, Constantinos H. Davos, Maria Tsoumani, Georgios Agrogiannis, Anastasia Konstantinidou, Eleni‐Dimitra Papanagnou, Ioannis P. Trougakos, Eftathios Kastritis, Zoi Kanaki, Efstathios K. Iliodromitis, Apostolos Klinakis, Meletios A Dimopoulos, Ioanna Andreadou, Evangelos Terpos

P4787Investigating the molecular mechanisms of carfilzomib-induced cardiotoxicity and the emerging role of metformin as a prophylactic therapy

Discussion(0)

Related publications

Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin

Elucidating Carfilzomib’s Induced Cardiotoxicity in an In Vivo Model of Aging: Prophylactic Potential of Metformin

The proteasome inhibitor carfilzomib (Cfz) induces cardiotoxicity in vivo: molecular mechanisms and the cardioprotective effect of metformin (Met)

Comparison of Proteasome Inhibitors-Induced Cardiotoxicity (carfilzomib vs. bortezomib): Insights into the Molecular Mechanisms

Metformin Restores AMPK Alpha-Mediated Autophagy and Prevents Carfilzomib-Induced Cardiotoxicity In Vivo